Progression-free survival was significantly greater in the nivolumab plus ipilimumab group compared to nivolumab alone. 2. Treatment-related adverse events were slightly higher in nivolumab plus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback